Aska Pharmaceuticals Of Japan Enhances Pipeline And Plans To Enter Generics Market
This article was originally published in PharmAsia News
Aska Pharmaceuticals President Takashi Yamaguchi expects menopausal symptoms drug Menoaid Patch will be NHI price-listed within the year. With an estimated ¥2 billion in potential sales, Aska will establish a team to prepare for next year's market launch. Aska has eight items in its pipeline, including Tavocept (dimensa), a neuropathy drug to reduce side effects of taking cancer drugs, that has shown promising results in Phase III trials in Japan. Yamaguchi also disclosed that the company plans to enter generics field with a focus on internal medicine, urology, OBGYN and otology drugs, Aska sets a ¥10 billion sales goal by fiscal year 2010. (Click here for more - Japanese language
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.